In Vivo Multidimensional Brain Imaging in Huntington’s Disease Animal Models - CEA - Commissariat à l’énergie atomique et aux énergies alternatives Accéder directement au contenu
Chapitre D'ouvrage Année : 2018

In Vivo Multidimensional Brain Imaging in Huntington’s Disease Animal Models

In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.

Résumé

Huntington's disease (HD) is a genetic neurodegenerative disorder caused by an abnormal expansion of a CAG repeat located in the gene encoding for huntingtin protein. This mutation induces the expression of a polyglutamine stretch in the mutated protein resulting in the modification of various biological properties of the wild-type protein and the progressive appearance of motor, cognitive, and psychiatric disorders that are typically associated to this condition. Although the exact neuropathological mechanisms of degeneration are still not fully understood, HD pathology is characterized by severe neuronal losses in various brain regions including the basal ganglia and many cortical areas. Early signs of astrogliosis may precede actual neuronal degeneration. Early metabolic impairment at least in part associated with mitochondrial complex II deficiency may play a key role in huntingtin-induced mechanisms of neurodegeneration. Clinical trials are actively prepared including various gene-silencing approaches aiming at decreasing mutated huntingtin production. However, with the lack of a specific imaging biomarker capable of visualizing mutated huntingtin or huntingtin aggregates, there is a need for surrogate markers of huntingtin neurodegeneration. MRI and caudate nucleus atrophy is one of the most sensitive imaging biomarkers of HD. As such it can be used as a means to study disease progression and potential halting of the neurodegenerative process by therapeutic intervention, but this marker relies on actual neuronal loss which is a somewhat a late event in the pathology. As a means to develop, characterize and evaluate new, potentially earlier biomarkers of HD pathology we have recently embarked on a series of NMR developments looking for brain imaging techniques that allow for noninvasive longitudinal evaluation/characterization of functional alterations in animal models of HD. This chapter describes an assemblage of innovative NMR methods that have proved useful in detecting pathological cell dysfunctions in various preclinical models of HD.
Fichier non déposé

Dates et versions

cea-02397804 , version 1 (06-12-2019)

Identifiants

Citer

Julien Flament, Philippe Hantraye, Julien Valette. In Vivo Multidimensional Brain Imaging in Huntington’s Disease Animal Models. Huntington's Disease, 1780, pp.285-301, 2018, ⟨10.1007/978-1-4939-7825-0_15⟩. ⟨cea-02397804⟩
18 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More